Killing Cancer
with Sound Waves
Histotripsy — the non-invasive therapy that uses focused ultrasound to liquify tumors through microscopic bubble clouds. No scalpel. No heat. No radiation.
🚨 WOW —Tumors literally liquefied by sound waves. No scalpel. No chemo. No radiation. None of those horrible side effects.
— Dr. Dawn Michael (@DawnsMission) March 27, 2026
This is histotripsy: focused ultrasound blasts destroy cancer cells mechanically in minutes, sparing healthy tissue completely. pic.twitter.com/7K4eiYjLYP
For decades, cancer treatment meant surgery, chemotherapy, radiation — or a painful combination. Now, a revolutionary technology is changing the game: histotripsy.
Developed at the University of Michigan and commercialized by HistoSonics, the Edison® Histotripsy System received FDA approval in October 2023 for treating liver tumors. In 2026, it continues to expand rapidly across major medical centers.
How Histotripsy Works
Precision mechanical destruction — not heat
Real-time Ultrasound Guidance
Doctors use live imaging to precisely target the tumor from outside the body.
High-Intensity Pulses
Ultra-short ultrasound pulses are delivered through the skin.
Acoustic Cavitation
Tiny gas bubbles form a “cloud” inside the tumor and violently collapse, shredding cancer cells at the subcellular level.
Natural Clearance
The liquified tumor debris is absorbed and cleared by the body’s immune system — often triggering an immune response against remaining cancer.
Why Patients & Doctors Love Histotripsy
A robotic arm precisely positions the transducer while real-time ultrasound imaging guides every pulse. Treatments typically last 30–90 minutes.
Clinical Results in 2026
in destroying targeted liver tumors (HOPE4LIVER trial and real-world data)
Most patients experience minimal side effects and rapid recovery
Liquefied tumor debris may help the immune system attack cancer elsewhere
Before and After Treatment
MRI images showing tumor (left) and ablation zone (right) after histotripsy
Expanding Beyond the Liver
Histotripsy is currently FDA-approved for liver tumors. Exciting progress is happening in 2026:
- 🩸Kidney tumors — Ongoing #HOPE4KIDNEY multi-center trial in the US and Europe. FDA approval expected soon.
- 🦠Pancreas — Preclinical and early clinical studies (including in Spain) show promising safety for targeting pancreatic tissue.
- 🔬Additional research exploring thyroid, prostate, and soft tissue tumors.
Join the Discussion